Wednesday, November 4, 2015
Arena Pharmaceuticals, based in San Diego, has announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its R&D priorities. As part of the initiative, Arena will reduce its U.S. workforce by about 80 employees or 35%, which Arena estimates will reduce annualized cash expenditures for personnel by about $11.0 million. Arena plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility.
Ultragenyx Pharmaceutical, a Novarto, Calif.-based biopharmaceutical company, and San Diego-based Arcturus Therapeutics, a leading RNA medicines company, have entered into a research collaboration and license agreement to discover and develop messenger RNA (mRNA) therapeutics to certain rare disease targets using Arcturus’ UNA Oligomer chemistry and LUNAR nanoparticle delivery platform. [Read More]
The FDA has approved Amgen’s Biologics License Application for IMLYGIC (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. [Read More]
San Diego-based Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, has initiated its phase II study of vepoloxamer for the treatment of patients with chronic heart failure. [Read More]
In an effort to accelerate timelines and decrease development costs of life-saving vaccines, the Infectious Disease Research Institute (IDRI) and Sanofi Pasteur have established the Global Health Vaccine Center of Innovation (GHVCI), to be based at IDRI in Seattle. The project is funded in part by a grant from the Bill & Melinda Gates Foundation. The GHVCI represents an alliance among the three organizations, focused on accelerating the development of vaccines and associated technologies to fight a wide range of global infectious diseases, and ensuring that those critical vaccines are accessible globally, especially to people in need within developing countries.